Dawn L. Hershman, MD, Herbert Irving Comprehensive Cancer Center at Columbia University
Advertisement
Articles by Dawn L. Hershman, MD, Herbert Irving Comprehensive Cancer Center at Columbia University
Advertisement
Latest Updated Articles
Rapid Readouts: Updated Results From KX-ORAX-001 StudyPublished: December 23rd 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5